Focus: Cancer Center Featured Story 2

• share
• favorite_border

Perioperative immunotherapy plus neoadjuvant chemotherapy significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC) compared to chemotherapy alone. Results from the Phase III CheckMate 77T study were presented today at the 2023 European Society of Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

• share
• favorite_border

Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in maintenance setting, according to researchers from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.

• share
• favorite_border

A UC Davis study shows the first-in-human imaging of the body’s CD8 T cell immune response to COVID-19 infection in recovering patients.

• share
• favorite_border

A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to enhance responses to immunotherapy in glioblastoma, potentially opening the door for wider use of engineered messenger RNA (mRNA) for cancer therapy. The study was published today in Nature Communications.

• share
• favorite_border

Researchers at The University of Texas MD Anderson Cancer Center have discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy, suggesting that lactic acid-producing bacteria present in various cancers may serve as novel therapeutic targets. The study, published today in Cancer Cell, reported that a particular bacterial species, Lactobacillus iners (L. iners), caused cancer cells to respond to radiation by rewiring metabolic signaling pathways to resist treatment. The researchers also found that L. iners was associated with poorer clinical outcomes in patients with cervical cancer.

• share
• favorite_border

Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain.

• share
• favorite_border

Yale Cancer Center researchers at Yale School of Medicine will present new cancer research at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, October 20 to 24. The annual meeting brings together clinicians, researchers, and patient advocates from all over the world. At ESMO 2023, oncologists will discuss new data and report updates on ongoing studies.

• share
• favorite_border

Ludwig Cancer Research announces its launch of the Ludwig Leadership Fellows Program, which aims to accelerate the careers of exceptional young scientists by helping them establish genuinely independent programs of research immediately after the completion of their graduate studies.

• share
• favorite_border

SEATTLE – OCTOBER 17, 2023 – Fred Hutchinson Cancer Center has announced the recipients of the 2023 Dr. Eddie Méndez Scholar Award, which recognizes early-career underrepresented minority scientists and scientists with disabilities.

• share
• favorite_border

In a new study published in Cell Chemical Biology, Moffitt Cancer Center researchers demonstrate this, showing that the ROS1 inhibitor lorlatinib has activity against an additional protein called PYK2. The team also reveals the mechanisms of this inhibition.

• share
• favorite_border

Daniel Herranz Benito, PhD, PharmD, resident researcher at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center and assistant professor of pharmacology at Rutgers Robert Wood Johnson Medical School, has received $800,000 from the V Foundation for Cancer Research, a premier cancer research charity, to support his research on acute lymphoblastic leukemia (ALL).

• share
• favorite_border

The Kraft Family Blood Donor Center, which provides lifesaving blood products to patients at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, announced today that it has finished implementing a more inclusive blood donation process, in alignment with updated guidelines issued by the U.S. Food and Drug Administration (FDA) that will allow many gay and bisexual men to donate blood and platelets.

• share
• favorite_border

New research in JNCCN finds that removing as much tumor as possible in multiorgan metastatic colorectal cancer—via various methods—did not cause a decrease in quality of life despite an increase in adverse events; survival benefits remain unclear.

• share
• favorite_border

Michael Berger, PhD, has been awarded a grant by The Israel Cancer Research Fund (ICRF) and the Cancer Research Institute (CRI).

• share
• favorite_border

The University of Texas MD Anderson Cancer Center will host its annual Leading Edge of Cancer Research Symposium Nov. 16-17, 2023, featuring presentations and discussions on genomics, immunity and inflammation, computational approaches for spatial biology, and emerging technologies that are driving the next wave of cancer breakthroughs.

• share
• favorite_border

In a new article published today in Science Translational Medicine, a team of Moffitt Cancer Center researchers, in collaboration with NFlection Therapeutics and researchers at Stanford University, reports the identification of a new drug, NFX-179, that can be applied to the skin and was shown to prevent the development of cutaneous squamous cell carcinoma in pre-clinical models.

• share
• favorite_border

Do you know your risk for breast and ovarian cancer? How about steps you can take to reduce your chances of developing cancer or what a family history might mean for your risk of the disease?